Clinical Trials on Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma in Singapore

Total 1 results

Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore

3

Subscribe